<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737464</url>
  </required_header>
  <id_info>
    <org_study_id>ML21810</org_study_id>
    <nct_id>NCT00737464</nct_id>
  </id_info>
  <brief_title>A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.</brief_title>
  <official_title>A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous MIRCERA for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single arm study will evaluate the maintenance of hemoglobin levels, safety and
      tolerability of once-monthly intravenous administration of Mircera in dialysis patients with
      chronic renal anemia. Patients will receive intravenous Mircera (120, 200 or 360 micrograms)
      every four weeks depending on the previous dose of epoetin alfa administered in the week
      preceding first study drug administration. Patients will be treated for 12 weeks with follow
      up 2 weeks after the last treatment visit. The anticipated time on study treatment is 3-12
      months, and the target sample size is 100-500 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2008</start_date>
  <completion_date type="Actual">September 12, 2009</completion_date>
  <primary_completion_date type="Actual">September 12, 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Maintaining Mean Hemoglobin Levels Within the Target Range During the Last 4 Weeks of the Treatment Period (Weeks 8 to 12)</measure>
    <time_frame>Weeks 8 to 12 (Last 4 weeks of treatment period)</time_frame>
    <description>Participants maintaining mean hemoglobin (Hb) concentration within the target range i.e. 10.0 - 12.0 gram per deciliter (g/dL) during last 4 weeks (Weeks 8 to 12) of treatment period (TP) were reported. Total duration for treatment period was 12 weeks. Stability verification period of 2-weeks was conducted before treatment period. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value Hb +/- 1 g/dL but not &gt;12.0 g/dL and not &lt;10.0 g/dL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Hemoglobin Concentration Between Stability Verification Period (Weeks -2 to -1) and Treatment Period (Weeks 8 to 12)</measure>
    <time_frame>SVP (Weeks -2 to -1) and TP (Weeks 8 to 12)</time_frame>
    <description>The mean change in Hb concentration between reference stability verification period (SVP) and in last 4 weeks (Weeks 8 to 12) of treatment period (TP) was reported. Duration for SVP was 2 weeks followed by treatment period of 12 weeks. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value hemoglobin +/- 1 g/dL but not &gt;12.0 g/dL and not &lt;10.0 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time Participants Spent Having Hemoglobin Range of 10.0 to 12.0 g/dL</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Mean time participants spent having hemoglobin range of 10.0 to 12.0 g/dL was reported. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value hemoglobin +/- 1 gram per deciliter but not &gt;12.0 g/dL and not &lt;10.0 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events, Serious Adverse Events and Deaths</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Participants with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and deaths in the overall study were reported. An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Heart Rate Over Time</measure>
    <time_frame>From Baseline (Week -1) to Weeks 0, 1, 2, 4, 6, 8, 10, and 12</time_frame>
    <description>Mean change from Baseline (Week -1) to end of the treatment (Week 12) in heart rate was reported. Baseline measure was considered as (Week -1) evaluation for this parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Blood Pressure (Systolic Blood Pressure and Diastolic Blood Pressure) Over Time</measure>
    <time_frame>From Baseline (Week -2) to Weeks -1, 0, 1, 2, 4, 6, 8, 10, and 12</time_frame>
    <description>Mean change from Baseline (Week -2) to end of the treatment (Week 12) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) before and after dialysis was reported. Baseline measure was considered as (Week -2) evaluation for this parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram</measure>
    <time_frame>At Week -2 and Week 12</time_frame>
    <description>Participants with abnormal electrocardiogram were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values of White Blood Cells and Platelets Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean values of white blood cells (WBCs), and platelets at Weeks -2, 4, 8, and 12 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values of Hypochromic Red Blood Cells Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean values of hypochromic red blood cells (RBCs) at Weeks -2, 4, 8, and 12 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Volume Levels Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean corpuscular volume (MCV) is a measure of the average red blood cell volume. MCV levels at Weeks -2, 4, 8, and 12 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values of Iron Parameters (Serum Iron and Total Iron Binding Capacity) Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean values of serum iron and total iron binding capacity (TIBC) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values of Serum Ferritin Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean values of serum ferritin were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values of Transferrin Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean values of transferrin were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values of Transferrin Saturation Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean values of Transferrin Saturation (TSAT) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values of Serum Albumin and Serum Globulin Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean values of serum albumin and serum globulin were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values of Aspartate Aminotransferase, Alanine Transaminase and Serum Alkaline Phosphatase Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean values of aspartate aminotransferase (AST), alanine transaminase (ALT) and serum alkaline phosphatase were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values of Serum Creatinine, Blood Urea Nitrogen, Serum Phosphate and Serum Bilirubin Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean values of serum creatinine, blood urea nitrogen (BUN), serum phosphate and serum bilirubin were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values of Serum Sodium and Serum Potassium Over Time</measure>
    <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
    <description>Mean values of serum sodium and serum potassium were reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Mircera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant with chronic renal anemia will receive methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methoxy polyethylene glycol-epoetin beta [Mircera]</intervention_name>
    <description>iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.</description>
    <arm_group_label>Mircera</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female patients, &gt;=18 years of age;

          -  chronic renal anemia;

          -  Hb concentration 10.5g/dL - 12.5g/dL;

          -  continuous intravenous maintenance therapy with epoetin alfa at the same dosing
             interval during the previous 2 months.

        Exclusion Criteria:

          -  blood transfusion within the previous 2 months;

          -  poorly controlled hypertension;

          -  significant acute or chronic bleeding;

          -  active malignant disease;

          -  congestive heart failure (NYHA Class IV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indraprastha Apollo Hospitals</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manipal Institute of Nephrology and Urology; Nephrology</name>
      <address>
        <city>Bangalore</city>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Asia Medical Centre - Hebbal; Nephrology</name>
      <address>
        <city>Bangalore</city>
        <zip>560024</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanker Foundation</name>
      <address>
        <city>Chennai</city>
        <zip>600 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MIOT Institute of Nephrology ; Nephrology</name>
      <address>
        <city>Chennai</city>
        <zip>6000089</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madras Medical Mission Hospital</name>
      <address>
        <city>Chennai</city>
        <zip>600037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Hospital</name>
      <address>
        <city>Guwahati</city>
        <zip>781005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamineni Hospitals; Nephrology</name>
      <address>
        <city>Hyderabad</city>
        <zip>500068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizam's Institute of Medical Sciences; Nephrology</name>
      <address>
        <city>Hyderabad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regency Hospital Ltd.; Nephrology</name>
      <address>
        <city>Kanpur</city>
        <zip>208005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wockhardt Hospital and Kidney Institute; Nephrology</name>
      <address>
        <city>Kolkata</city>
        <zip>700029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meerut Kidney Hospital</name>
      <address>
        <city>Meerut</city>
        <zip>250001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silver Oaks Hospital; Nephrology</name>
      <address>
        <city>Mohali</city>
        <zip>160 063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Kidney Care</name>
      <address>
        <city>Mumbai</city>
        <zip>400080</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancelot Dialysis Center</name>
      <address>
        <city>Mumbai</city>
        <zip>400092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Flt. Lt. Rajan Dhall Hospital; Nephrology</name>
      <address>
        <city>New Delhi</city>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <zip>411 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2008</study_first_submitted>
  <study_first_submitted_qc>August 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2008</study_first_posted>
  <results_first_submitted>February 25, 2016</results_first_submitted>
  <results_first_submitted_qc>March 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2016</results_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 132 participants were enrolled from 26 August 2008 to 12 September 2009 at 11 study sites in India.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Mircera</title>
          <description>Eligible participants with chronic renal anemia were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other - Failure to Return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment / Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all enrolled participants who received at least one dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Mircera</title>
          <description>Eligible participants with chronic renal anemia were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="132"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.74" spread="12.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Maintaining Mean Hemoglobin Levels Within the Target Range During the Last 4 Weeks of the Treatment Period (Weeks 8 to 12)</title>
        <description>Participants maintaining mean hemoglobin (Hb) concentration within the target range i.e. 10.0 – 12.0 gram per deciliter (g/dL) during last 4 weeks (Weeks 8 to 12) of treatment period (TP) were reported. Total duration for treatment period was 12 weeks. Stability verification period of 2-weeks was conducted before treatment period. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value Hb +/- 1 g/dL but not &gt;12.0 g/dL and not &lt;10.0 g/dL.</description>
        <time_frame>Weeks 8 to 12 (Last 4 weeks of treatment period)</time_frame>
        <population>Per-protocol (PP) population comprised of participants who had received at least 1 dose of MIRCERA (Week 0) and for whom data for at least one follow-up variable was available and who had completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Maintaining Mean Hemoglobin Levels Within the Target Range During the Last 4 Weeks of the Treatment Period (Weeks 8 to 12)</title>
          <description>Participants maintaining mean hemoglobin (Hb) concentration within the target range i.e. 10.0 – 12.0 gram per deciliter (g/dL) during last 4 weeks (Weeks 8 to 12) of treatment period (TP) were reported. Total duration for treatment period was 12 weeks. Stability verification period of 2-weeks was conducted before treatment period. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value Hb +/- 1 g/dL but not &gt;12.0 g/dL and not &lt;10.0 g/dL.</description>
          <population>Per-protocol (PP) population comprised of participants who had received at least 1 dose of MIRCERA (Week 0) and for whom data for at least one follow-up variable was available and who had completed the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.89" lower_limit="48.29" upper_limit="67.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hemoglobin Concentration Between Stability Verification Period (Weeks -2 to -1) and Treatment Period (Weeks 8 to 12)</title>
        <description>The mean change in Hb concentration between reference stability verification period (SVP) and in last 4 weeks (Weeks 8 to 12) of treatment period (TP) was reported. Duration for SVP was 2 weeks followed by treatment period of 12 weeks. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value hemoglobin +/- 1 g/dL but not &gt;12.0 g/dL and not &lt;10.0 g/dL.</description>
        <time_frame>SVP (Weeks -2 to -1) and TP (Weeks 8 to 12)</time_frame>
        <population>Per-protocol (PP) population comprised of participants who had received at least 1 dose of MIRCERA (Week 0) and for whom data for at least one follow-up variable was available and who had completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hemoglobin Concentration Between Stability Verification Period (Weeks -2 to -1) and Treatment Period (Weeks 8 to 12)</title>
          <description>The mean change in Hb concentration between reference stability verification period (SVP) and in last 4 weeks (Weeks 8 to 12) of treatment period (TP) was reported. Duration for SVP was 2 weeks followed by treatment period of 12 weeks. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value hemoglobin +/- 1 g/dL but not &gt;12.0 g/dL and not &lt;10.0 g/dL.</description>
          <population>Per-protocol (PP) population comprised of participants who had received at least 1 dose of MIRCERA (Week 0) and for whom data for at least one follow-up variable was available and who had completed the study.</population>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hb in SVP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.76" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Avg of Hb in Last 4 Weeks TP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.28" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.52</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Time Participants Spent Having Hemoglobin Range of 10.0 to 12.0 g/dL</title>
        <description>Mean time participants spent having hemoglobin range of 10.0 to 12.0 g/dL was reported. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value hemoglobin +/- 1 gram per deciliter but not &gt;12.0 g/dL and not &lt;10.0 g/dL.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Per-protocol (PP) population comprised of participants who had received at least 1 dose of MIRCERA (Week 0) and for whom data for at least one follow-up variable was available and who had completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time Participants Spent Having Hemoglobin Range of 10.0 to 12.0 g/dL</title>
          <description>Mean time participants spent having hemoglobin range of 10.0 to 12.0 g/dL was reported. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value hemoglobin +/- 1 gram per deciliter but not &gt;12.0 g/dL and not &lt;10.0 g/dL.</description>
          <population>Per-protocol (PP) population comprised of participants who had received at least 1 dose of MIRCERA (Week 0) and for whom data for at least one follow-up variable was available and who had completed the study.</population>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events, Serious Adverse Events and Deaths</title>
        <description>Participants with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and deaths in the overall study were reported. An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to Week 14</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events, Serious Adverse Events and Deaths</title>
          <description>Participants with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and deaths in the overall study were reported. An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Heart Rate Over Time</title>
        <description>Mean change from Baseline (Week -1) to end of the treatment (Week 12) in heart rate was reported. Baseline measure was considered as (Week -1) evaluation for this parameter.</description>
        <time_frame>From Baseline (Week -1) to Weeks 0, 1, 2, 4, 6, 8, 10, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Heart Rate Over Time</title>
          <description>Mean change from Baseline (Week -1) to end of the treatment (Week 12) in heart rate was reported. Baseline measure was considered as (Week -1) evaluation for this parameter.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>Beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate, Week -1, (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.79" spread="7.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Week 0, (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.54" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Week 1, (n = 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.64" spread="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Week 2, (n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.98" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Week 4, (n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.61" spread="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Week 6, (n = 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.55" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Week 8, (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.83" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Week 10, (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.56" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Week 12, (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.80" spread="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Blood Pressure (Systolic Blood Pressure and Diastolic Blood Pressure) Over Time</title>
        <description>Mean change from Baseline (Week -2) to end of the treatment (Week 12) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) before and after dialysis was reported. Baseline measure was considered as (Week -2) evaluation for this parameter.</description>
        <time_frame>From Baseline (Week -2) to Weeks -1, 0, 1, 2, 4, 6, 8, 10, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = the number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Blood Pressure (Systolic Blood Pressure and Diastolic Blood Pressure) Over Time</title>
          <description>Mean change from Baseline (Week -2) to end of the treatment (Week 12) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) before and after dialysis was reported. Baseline measure was considered as (Week -2) evaluation for this parameter.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = the number of participants analyzed at a given time point.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Week-2, Before Dialysis (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.04" spread="15.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week-2, After Dialysis (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.51" spread="18.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week-1, Before Dialysis (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.72" spread="14.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week-1, After Dialysis (n =131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.26" spread="18.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 0, Before Dialysis (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.05" spread="16.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 0, After Dialysis (n = 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.75" spread="16.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 1, Before Dialysis (n = 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.02" spread="17.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 1, After Dialysis (n = 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.02" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 2, Before Dialysis (n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.85" spread="18.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 2, After Dialysis (n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.92" spread="18.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 4, Before Dialysis (n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.68" spread="16.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 4, After Dialysis (n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.65" spread="18.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 6, Before Dialysis (n = 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.16" spread="18.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 6, After Dialysis (n = 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.55" spread="20.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 8, Before Dialysis (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.77" spread="18.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 8, After Dialysis (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.42" spread="17.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 10, Before Dialysis (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.14" spread="17.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 10, After Dialysis (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.98" spread="17.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 12, Before Dialysis (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.55" spread="18.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 12, After Dialysis (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.80" spread="18.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week -2, Before Dialysis (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.92" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week -2, After Dialysis (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.05" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week -1, Before Dialysis (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.90" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week -1, After Dialysis (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.22" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 0, Before Dialysis (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.05" spread="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 0, After Dialysis (n = 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.04" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 1, Before Dialysis (n = 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.68" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 1, After Dialysis (n = 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.27" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 2, Before Dialysis (n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.77" spread="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 2, After Dialysis (n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.69" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 4, Before Dialysis (n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.15" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 4, After Dialysis (n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.29" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 6, Before Dialysis (n = 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.31" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 6, After Dialysis (n = 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.97" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 8, Before Dialysis (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.28" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 8, After Dialysis (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.35" spread="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 10, Before Dialysis (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.91" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 10, After Dialysis (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.33" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 12, Before Dialysis (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.17" spread="10.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 12, After Dialysis (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.23" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Electrocardiogram</title>
        <description>Participants with abnormal electrocardiogram were reported.</description>
        <time_frame>At Week -2 and Week 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = the number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram</title>
          <description>Participants with abnormal electrocardiogram were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = the number of participants analyzed at a given time point.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week -2 (n=132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values of White Blood Cells and Platelets Over Time</title>
        <description>Mean values of white blood cells (WBCs), and platelets at Weeks -2, 4, 8, and 12 were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values of White Blood Cells and Platelets Over Time</title>
          <description>Mean values of white blood cells (WBCs), and platelets at Weeks -2, 4, 8, and 12 were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>Per cubic millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WBCs, Week -2 (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7527.50" spread="2444.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBCs, Week 4 (n = 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7369.74" spread="2470.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBCs, Week 8 (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7506.61" spread="2214.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBCs, Week 12 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7484.35" spread="2130.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Week -2 (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211772.73" spread="73360.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Week 4 (n = 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199508.77" spread="64724.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Week 8 (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208745.76" spread="67546.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Week 12 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208566.37" spread="102269.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values of Hypochromic Red Blood Cells Over Time</title>
        <description>Mean values of hypochromic red blood cells (RBCs) at Weeks -2, 4, 8, and 12 were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values of Hypochromic Red Blood Cells Over Time</title>
          <description>Mean values of hypochromic red blood cells (RBCs) at Weeks -2, 4, 8, and 12 were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>Percentage of RBCs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypochromic RBCs, Week -2 (n = 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypochromic RBCs, Week 4 (n = 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypochromic RBCs, Week 8 (n = 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypochromic RBCs, Week 12 (n = 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscular Volume Levels Over Time</title>
        <description>Mean corpuscular volume (MCV) is a measure of the average red blood cell volume. MCV levels at Weeks -2, 4, 8, and 12 were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscular Volume Levels Over Time</title>
          <description>Mean corpuscular volume (MCV) is a measure of the average red blood cell volume. MCV levels at Weeks -2, 4, 8, and 12 were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCV, Week -2 (n = 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.32" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV, Week 4 (n = 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.99" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV, Week 8 (n = 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.41" spread="7.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV, Week 12 (n = 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.09" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values of Iron Parameters (Serum Iron and Total Iron Binding Capacity) Over Time</title>
        <description>Mean values of serum iron and total iron binding capacity (TIBC) were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values of Iron Parameters (Serum Iron and Total Iron Binding Capacity) Over Time</title>
          <description>Mean values of serum iron and total iron binding capacity (TIBC) were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>microgram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Iron, Week -2 (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.13" spread="77.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Iron, Week 4 (n = 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.56" spread="59.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Iron, Week 8 (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.79" spread="67.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Iron, Week 12 (n = 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.53" spread="56.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIBC, Week -2 (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.44" spread="114.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIBC, Week 4 (n = 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.98" spread="116.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIBC, Week 8 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283.50" spread="133.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIBC, Week 12 (n = 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.43" spread="118.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values of Serum Ferritin Over Time</title>
        <description>Mean values of serum ferritin were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values of Serum Ferritin Over Time</title>
          <description>Mean values of serum ferritin were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>nanogram per mililiter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Ferritin, Week -2 (n = 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1806.30" spread="6418.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Ferritin, Week 4 (n = 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1422.48" spread="2550.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Ferritin, Week 8 (n = 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1109.07" spread="1050.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Ferritin, Week 12 (n = 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1109.80" spread="1016.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values of Transferrin Over Time</title>
        <description>Mean values of transferrin were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values of Transferrin Over Time</title>
          <description>Mean values of transferrin were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>miligram per mililiter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Transferrin, Week -2 (n = 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.24" spread="54.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transferrin, Week 4 (n = 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.00" spread="40.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transferrin, Week 8 (n = 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.72" spread="40.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transferrin, Week 12 (n = 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.22" spread="36.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values of Transferrin Saturation Over Time</title>
        <description>Mean values of Transferrin Saturation (TSAT) were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values of Transferrin Saturation Over Time</title>
          <description>Mean values of Transferrin Saturation (TSAT) were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TSAT, Week -2 (n = 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.55" spread="38.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSAT, Week 4 (n = 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.70" spread="36.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSAT, Week 8 (n = 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.08" spread="31.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSAT, Week 12 (n = 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.71" spread="29.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values of Serum Albumin and Serum Globulin Over Time</title>
        <description>Mean values of serum albumin and serum globulin were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values of Serum Albumin and Serum Globulin Over Time</title>
          <description>Mean values of serum albumin and serum globulin were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>gram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Albumin, Week -2 (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Albumin, Week 4 (n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Albumin, Week 8 (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Albumin, Week 12 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Globulin, Week -2 (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Globulin, Week 4 (n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Globulin, Week 8 (n = 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Globulin, Week 12 (n = 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values of Aspartate Aminotransferase, Alanine Transaminase and Serum Alkaline Phosphatase Over Time</title>
        <description>Mean values of aspartate aminotransferase (AST), alanine transaminase (ALT) and serum alkaline phosphatase were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values of Aspartate Aminotransferase, Alanine Transaminase and Serum Alkaline Phosphatase Over Time</title>
          <description>Mean values of aspartate aminotransferase (AST), alanine transaminase (ALT) and serum alkaline phosphatase were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>units per litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST, Week -2 (n = 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.48" spread="18.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 4 (n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.26" spread="12.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 8 (n = 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.86" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 12 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.17" spread="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week -2 (n = 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.34" spread="27.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 4 (n = 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.18" spread="18.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 8 (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.44" spread="20.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 12 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.07" spread="20.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Alkaline Phosphatase, Week -2 (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.7" spread="110.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Alkaline Phosphatase, Week 4 (n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.3" spread="108.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Alkaline Phosphatase, Week 8 (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.1" spread="123.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Alkaline Phosphatase, Week 12 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.3" spread="100.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values of Serum Creatinine, Blood Urea Nitrogen, Serum Phosphate and Serum Bilirubin Over Time</title>
        <description>Mean values of serum creatinine, blood urea nitrogen (BUN), serum phosphate and serum bilirubin were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values of Serum Creatinine, Blood Urea Nitrogen, Serum Phosphate and Serum Bilirubin Over Time</title>
          <description>Mean values of serum creatinine, blood urea nitrogen (BUN), serum phosphate and serum bilirubin were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>miligram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Creatinine, Week -2 (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.89" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Creatinine, Week 4 (n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.34" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Creatinine, Week 8 (n = 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.03" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Creatinine, Week 12 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.19" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN, Week -2 (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.72" spread="29.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN, Week 4 (n = 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.67" spread="27.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN, Week 8 (n = 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.10" spread="32.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN, Week 12 (n = 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.79" spread="35.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Phosphate, Week -2 (n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Phosphate, Week 4 (n = 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Phosphate, Week 8 (n = 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Phosphate, Week 12 (n = 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.37" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Bilirubin, Week -2 (n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Bilirubin, Week 4 (n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Bilirubin, Week 8 (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Bilirubin, Week 12 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values of Serum Sodium and Serum Potassium Over Time</title>
        <description>Mean values of serum sodium and serum potassium were reported.</description>
        <time_frame>At Weeks -2, 4, 8, and 12</time_frame>
        <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Eligible participants were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values of Serum Sodium and Serum Potassium Over Time</title>
          <description>Mean values of serum sodium and serum potassium were reported.</description>
          <population>Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.</population>
          <units>millimole per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Potassium, Week -2 (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium, Week 4 (n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.26" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium, Week 8 (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium, Week 12 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium, Week -2 (n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.1" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium, Week 4 (n = 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.2" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium, Week 8 (n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.0" spread="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium, Week 12 (n = 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.9" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 14</time_frame>
      <desc>SAEs and non-serious AEs were reported for the safety population which included all participants who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mircera</title>
          <description>Eligible participants with chronic renal anemia were administered methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Peritoneal dialysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roche Trial Information Hotline</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

